UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 194

Sortiert nach

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials

Journal of thoracic oncology, 2019-08, Vol.14 (8), p.1440-1446

2019

Link zum Volltext

Verfügbarkeit prüfen

Medical oncology group of Australia: taking a leading role in medical oncology education, patient care & research

Annals of oncology, 2018-10, Vol.29, p.vii5-vii5

Karapetis, Christos S.

2018

Link zum Volltext

Verfügbarkeit prüfen

Re: Workforce challenges across Victorian medical oncology services: review consultations and workload

Internal medicine journal, 2023-06, Vol.53 (6), p.1093-1093

2023

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350

2018

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

International journal of cancer, 2021-02, Vol.148 (4), p.1014-1026

2021

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab for the Treatment of Colorectal Cancer

The New England journal of medicine, 2007-11, Vol.357 (20), p.2040-2048

2007

Link zum Volltext

Verfügbarkeit prüfen

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Journal of clinical oncology, 2012-10, Vol.30 (29), p.3588-3595

2012

Link zum Volltext

Verfügbarkeit prüfen

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2021-04, Vol.39 (11), p.1253-1263

2021

Link zum Volltext

Verfügbarkeit prüfen

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern

Acta oncologica, 2018-11, Vol.57 (11), p.1438-1444

2018

Link zum Volltext

Verfügbarkeit prüfen

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

The New England journal of medicine, 2008-10, Vol.359 (17), p.1757-1765

2008

Link zum Volltext

Verfügbarkeit prüfen

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

JAMA : the journal of the American Medical Association, 2010-10, Vol.304 (16), p.1812

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials

Journal of thoracic oncology, 2022-06, Vol.17 (6), p.758-767

2022

Link zum Volltext

Verfügbarkeit prüfen

Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis

ANZ journal of surgery, 2023-07, Vol.93 (7-8), p.1847-1853

2023

Link zum Volltext

Verfügbarkeit prüfen

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer

Clinical colorectal cancer, 2016-06, Vol.15 (2), p.95-103

2016

Link zum Volltext

Verfügbarkeit prüfen

Localised prostate cancer in elderly men aged 80–89 years, findings from a population‐based registry

BJU international, 2018-05, Vol.121 (S3), p.48-54

2018

Link zum Volltext

Verfügbarkeit prüfen

First‐line therapy for metastatic colorectal cancer: Current perspectives and future directions

Asia-Pacific journal of clinical oncology, 2019-02, Vol.15 (S1), p.3-14

2019

Link zum Volltext

Verfügbarkeit prüfen

Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.e208-e208

2019

Link zum Volltext

Verfügbarkeit prüfen

Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying

Internal medicine journal, 2018-07, Vol.48 (7), p.774-779

2018

Link zum Volltext

Verfügbarkeit prüfen

Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival

Journal of cancer research and clinical oncology, 2018-09, Vol.144 (9), p.1741-1750

2018

Link zum Volltext

Verfügbarkeit prüfen

Response to: “Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases”

Annals of surgery, 2018-07, Vol.268 (1), p.e9-e10

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial

JCO oncology practice, 2023-06, Vol.19 (6), p.e859

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 194

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(182)

Publikationsform

Artikel
(194)

Sprache

Englisch
(194)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(91)
Science & Technology
(91)
Humans
(78)
Oncology
(68)
Female
(41)
Male
(40)
Middle Aged
(37)
Aged
(36)
Chemotherapy
(34)
Cancer
(29)
Adult
(27)
Survival
(27)
Colorectal Cancer
(25)
Aged, 80 And Over
(22)
Colorectal Neoplasms - Pathology
(21)
Colorectal Neoplasms - Drug Therapy
(20)
Tumors
(20)
Prognosis
(18)
Mutation
(17)
Patients
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials

Medical oncology group of Australia: taking a leading role in medical oncology education, patient care & research

Re: Workforce challenges across Victorian medical oncology services: review consultations and workload

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

Cetuximab for the Treatment of Colorectal Cancer

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials

Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer

Localised prostate cancer in elderly men aged 80–89 years, findings from a population‐based registry

First‐line therapy for metastatic colorectal cancer: Current perspectives and future directions

Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary

Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival

Response to: “Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases”

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial

Aktive Filter

Suchergebnisse filtern